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Abstract
Background: Fusarium species are ubiquitous environmental fungi that occasionally provoke serious invasive
infections in immunocompromised hosts. Among Fusarium species, Fusarium ramigenum, belonging to the
Fusarium fujikuroi species complex, has thus far never been found to cause human infections. Here we describe the
first case of invasive fusariosis caused by Fusarium ramigenum in a human and also identify immunological
deficiencies that most likely contributed to invasiveness.
Case presentation: A 32-year-old Caucasian male with a seemingly insignificant medical history of mild respiratory
illness during the preceding two years, developed invasive pulmonary fusariosis. Detailed immunological assessment
revealed the presence of common variable immunodeficiency, complicated by a severe impairment of the capacity
of T-cells to produce both gamma-interferon and interleukin-17. In-depth microbiological assessment identified the
novel human opportunistic pathogen Fusarium ramigenum as cause of the infection.
Conclusion: This report demonstrated that an opportunistic invasive fungal infection may indicate an underlying
cellular immune impairment of the host. The unexpected invasive infection with Fusarium ramigenum in this case
unmasked a complex combined humoral and cellular immunological deficiency.
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Background
Fusarium species are common saprophytic fungi that
globally represent the third cause of invasive mould in-
fection in humans, after Aspergillus and after Mucorales.
This opportunistic infection is common in Brazil but
rare in other parts of the world. The important Fusarium
species implicated in human pathology belong to the F.
solani, F. oxysporum, and F. fujikuroi species complexes
[1]. In immunocompetent hosts, clinical manifestations
are relatively mild and mostly result from accidental
trauma (e.g. keratitis and contact lens-related infections,
onychomycosis, osteo-arthritis, but also peritonitis after
peritoneal dialysis). Invasive infections are almost exclu-
sively found in immunodeficient hosts, particularly those
with severe dysfunction of cellular immunity [2, 3]. In
those patients, infections of the respiratory tract are com-
monly encountered. Mortality due to invasive fusariosis
can be above 50 %, even when appropriate and intensive
therapeutic management is applied [1, 4]. Here we
describe a case of invasive fusariosis caused by a hitherto
unknown opportunist, Fusarium ramigenum, and report
on the immunological causes most likely contributing to
this infection.
Case report
A 32-year-old Caucasian male, an outdoor worker (border
guard), with mild, recurrent respiratory infections during
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two preceding years was admitted to the infectious dis-
eases clinic with a 5-day history of high fever, chills, chest
pain, dry cough and myalgia. Physical examination showed
a good general condition, 38.5 °C fever, no crackles on
auscultation, and a palpable spleen (15 cm length). Pul-
monary imaging (chest X-ray and lung CT-scan) demon-
strated bilateral pulmonary micro-nodular infiltrations and
satellite mediastinal lymphadenopathies with a maximum
diameter of 16 mm (Fig. 1). Laboratory investigations
revealed leukocytosis (15000/mm3) with neutrophilia
(11700/mm3), mild thrombocytopenia (120000/mm3), and
elevated inflammatory markers (CRP 51 mg/L, ESR
17 mm/h, fibrinogen 416 mg/dl). Serological tests for
atypical pathogens (Chlamydia, Mycoplasma, Coxiella,
Legionella) and Quantiferon for tuberculosis were
negative. Blood cultures were also negative.
The initial empirical therapy consisted of moxifloxacin
for 2 weeks and non-steroidal anti-inflammatory drugs.
The clinical course was unsatisfactory except for a partial
decline of fever in the first days but a persistent low-
grade fever remained. A broncho-alveolar lavage (BAL)
was performed 10 days after admission. Cytology of the
BAL fluid was consistent with hemorrhagic lymphocytic
alveolitis. No microorganisms were observed during
direct microscopical examination. However on the
Sabouraud’s glucose agar (SGA) there was a growth of
colonies with cottony aerial hyphae which were white,
with a light shade of purple and which grew from a
pinkish submerged mycelium. The colonies were pheno-
typically identified as Fusarium spp. on the basis of
curved, septate conidia (Fig. 2). At this point, invasive
fungal infection was not demonstrated and the positive
Fusarium culture was interpreted as fungal colonization
in an apparently immunocompetent patient. Subsequent
examination of the patient’s immune system showed a
severe hypogammaglobulinemia (0.13 g/l) involving all
three analyzed lines: IgM < 0.17, IgG < 0.89, and IgA <
0.24 (g/l). CD4 T-cells were moderately decreased to 468
per cubic mm (33 %), while CD8 T-cells were 745 per
cubic mm (53 %), with a low CD4/CD8 ratio (0.63).
Investigations regarding a possible acquired hypogam-
maglobulinemia (autoimmune diseases, viral infections
including HIV, hematologic malignancies) failed to give
a clue, suggesting the final clinical diagnosis as being
common variable immunodeficiency (CVID). Bone mar-
row biopsy was normal. The patient was substituted
intravenously with immunoglobulins (25 g/day, 5 days).
The diagnosis of the patient’s immune deficiency chan-
ged the medical judgment of the case, and now an invasive
fungal disease being taken into account. Subsequently,
voriconazole was added to the therapeutic plan at day 14
after admission (6 mg/kg IV q12h for first 24 h, then
4 mg/kg IV q12h for 2 weeks, then 200 mg orally q12h,
with a total duration of six weeks). A voriconazole E test
showed an MIC of 2 mg/L. The patient responded with an
initial good clinical improvement.
Fig. 1 a Chest X-ray: bilateral micro-nodular alveolar infiltrates, predominantly in inferior areas; b Chest CT-scan: same aspects
Fig. 2 a Culture on SGA plate: Fusarium colonies; b Direct microscopic examination of Fusarium with segmented hyphae and conidia x200;
c Methylene blue stained slide from Fusarium culture with banana-shaped conidia, x1200
Moroti et al. BMC Infectious Diseases  (2016) 16:79 Page 2 of 6
Three weeks after cessation of voriconazole, the patient
was re-admitted with productive cough, without fever.
Physical examination revealed bilateral, rough vesicular
murmurs and a CT-scan showed progressive pulmonary
lesions. A significant increase of alveolar infiltrates with
extension to the superior regions of the lungs and multiple
new spherical dense masses (<5 mm diameter) were
observed. A new BAL was performed and the cytology
showed the same aspect as few weeks previously
(hemorrhagic alveolitis), while the culture was again posi-
tive for a Fusarium species. IgA, IgG and IgM had again
very low values and needed substitution. A second anti-
fungal treatment course with voriconazole was started
(same protocol as first course).
A lung biopsy was performed at day 8 after voricona-
zole reinitiation (3 months after first admission). Immu-
nohistochemical examination excluded lung lymphoma
and confirmed a reactive cell pattern (interstitial lymph-
oid infiltrate). Hyaline hyphae were detected in smears
from lung tissue imprints (Fig. 3), suggesting an invasive
pulmonary fungal disease.
The patient’s immunological status, i.e. the CVID, is a
humoral deficit and even in severe forms invasive fungal
diseases are rare. Therefore the cellular immune profile
was further analyzed and an important qualitative cellu-
lar deficiency was additionally found: a defective produc-
tion of both gamma-interferon- γ (IFN-γ) and IL-17.
Deficient cytokine production was demonstrated using a
method of whole blood stimulation with specific anti-
gens [5]. The patient’s whole blood IFN-γ production,
72 h after stimulation with heat-killed Candida albicans
yeast cells (CA), phytohemagglutinin (PHA) and staphylo-
coccal antigen (SA), was 16, 1000 and 12 pg/ml, respect-
ively, and was much lower than the production of 7160,
>10000 and 1620 pg/ml of healthy volunteers. IL-17 pro-
duction after stimulation with PHA was 465 and 300 pg/
ml in the volunteers, while values were below detection
limit in our patient in both in-duplo stimulations. Can-
dida albicans and S. aureus did not stimulate IL-17 pro-
duction in the whole blood stimulation system (Table 1).
The evolution was favorable under prolonged antifun-
gal therapy with voriconazole for 6 months and con-
tinuous immunoglobulin substitution with 25 g/day,
5 days per month. A CT-scan after 6 months showed
regression of the pulmonary lesions. The subsequent
BAL was culture-negative for Fusarium and no signs of
hemorrhagic lymphocytic alveolitis were seen. Antifun-
gal treatment was stopped and during two years of
follow-up (CT-scan, respiratory functional tests) no fur-
ther progression was noted.
Fig. 3 a Inflammatory lymphocytic nodular and focal infiltrate with fibrosis (HE stain × 100); b Inflammatory reaction and hyphae on pulmonary
biopsy smear (Gram stain × 1200)
Table 1 Cytokine production after whole blood stimulation at
24 h (for TNF and for IL-6) and at 72 h (for IFNγ and IL-17)
24 h IFNγ Contr.1 Contr.2 Pat.1 Pat.2
RPMI <78 <78 <78 <78
CA 3270 3130 1120 890
PHA 960 1360 170 220
SA 4810 7480 2430 2560
24 h IL 6 contr.1 contr.2 pat.1 pat.2
RPMI 32 63 48 26
CA 4700 4100 1730 1560
PHA 1535 1900 265 325
SA 12500 14000 9500 8700
72 h IFNγ contr.1 contr.2 pat.1 pat.2
RPMI 10 9 9 <8
CA 8940 7160 16 <8
PHA 8300 >10000 1000 834
SA 1280 1620 12 8
72 h IL 17 contr.1 contr.2 pat.1 pat.2
RPMI <40 <40 <40 <40
CA <40 <40 <40 <40
PHA 300 465 <40 <40
SA <40 <40 <40 <40
Whole blood was stimulated either with RPMI culture medium (unstimulated
control), with heat-killed C. albicans (CA), phytohemagluttinine (PHA) or heat-
killed S. aureus (SA). Concentrations of the cytokine produced are expressed
as pg/mL
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Further identification of the fungus was undertaken at
the CBS-KNAW Fungal Biodiversity Centre in Utrecht,
The Netherlands, under accession number CBS 140388.
Sequencing of partial elongation factor 1 alpha (TEF1)
and beta-tubulin (BT2) genes was performed. Blast
results with sequences in GenBank revealed that this
fungus belonged to the Fusarium fujikuroi complex. In
order to establish the phylogenetic position of this clin-
ical isolate, a general tree was made with MrBayes v.
3.1.2 on the Cipres Portal based on the sequenced BT2
(500 bp) and TEF-1 (600 bp) regions. Thirty-six species
within the Fusarium fujikuroi species complex were
selected for phylogenetic analyses of combined BT2 and
TEF1 fragments. Our strain was nested with a F. rami-
genum subclade (Fig. 4). Sequences of this novel human
opportunistic fungus (CBS 140388) were deposited in
GenBank with accession numbers KT794172 for BT2
and KT794175 for TEF1, respectively.
Antifungal susceptibility testing performed with broth
microdilution according to CLSI M38A resulted in the
following MICs/MECs: amphotericin B, 1 mg/L; posaco-
nazole, 1 mg/L; itraconazole, >16 mg/L; voriconazole,
2 mg/L; isavuconazole, 4 mg/L and anidulafungin and
micafungin both > 8 mg/L.
Fig. 4 Phylogenetic analysis of Fusarium ramigenum. Phylogenetic reconstruction obtained from Bayesian inference of two combined loci (TEF1
and BT2) using MrBayes v. 3.1.2. Values at branch node indicate branch support with posterior probabilities (PP; values≥ 0.80 shown) and
branches in boldface = bootstrapping percentages based on Maximum Likelihood (ML). The tree was rooted with two strains of F. inflexum
NRRL20433 and F. oxysporum NRRL22902
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Discussion
We describe a patient with CVID and cellular T-
helper-defects who developed an invasive infection
with Fusarium ramigenum. After long-term treatment
with voriconazole (6 months) and immunoglobulin
substitution, the patient recovered from this opportunistic
infection. To the best of our knowledge, this is the first
case in which F. ramigenum was described as a cause of
invasive infection in a human patient, reinforcing the sig-
nificance of the F. fujikuroi species complex as opportun-
istic pathogens in immunocompromised hosts. The
fungus cultured from BAL specimens of this patient with
atypical pneumonia and no significant medical history first
suggested fungal colonization rather than infection. More-
over, the observed BAL cytology, indicating hemorrhagic
lymphocytic alveolitis, could neither prove nor exclude a
fungus induced inflammatory reaction. However, the re-
lapse of Fusarium infection after a short 6-week course of
antimycotic therapy (6 weeks) raised the suspicion of an
invasive infection. The microscopic findings of hyaline hy-
phae in the lung biopsy confirmed the invasive fusariosis.
This was further supported by the identification of com-
bined humoral (severe pan-hypogammaglobulinemia) and
cellular (defective IFN- γ and IL-17 production capacity)
immune defects that are known to be crucial for antifun-
gal host defense [6, 7].
The initial humoral immunological deficit identified, i.e.
severe pan-hypogammaglobulinemia, was not consistent
with an invasive fungal infection. The slightly lowered
CD4 T-cell counts, combined with a reduced T-cell
CD4:CD8 ratio, could not explain this opportunistic infec-
tion either, and therefore we embarked on functional as-
says to test the T-helper functions. Subsequent analysis
revealed an important deficiency, with very low levels of
IFN-γ and a deficit in IL-17 production capacity. Cellular
defects in CVID patients have been reported previously,
and this is the most likely explanation of the observed
infection [8, 9]. The results are in consensus with the
latest data in the literature, describing the possibility of
complex T-cell abnormalities in association with CVID.
T-cell abnormalities associated with CVID generate a
slight quantitative deficit of CD4 lymphocytes, an abnor-
mal CD4/CD8 ratio, and a qualitative deficit in cytokine
production [10–14]. The exact mechanisms and genetic
causes of these defects in CVID remain to be elucidated.
Alternatively, a different explanation may be represented
by defects in genes known to be crucial for antifungal host
defense, such as the CARD9 adaptor [6, 7].
An important aspect of this clinical case is the first
identification of a novel human opportunistic fungus, F.
ramigenum as cause of the infection. This fungus
belongs to the relatively frequently encountered F.
fujikuroi complex, but molecular analysis identified F.
ramigenum, a species not figuring on the list of species
known to occur in human or animal infections [15].
Fusarium ramigenum was first described in 1998 from
inedible wild Capri figs in California, U.S.A. [16]. The
species produced fusaric acid, beauvericin and fumo-
nisin [17]. Its pattern of susceptibility to antimycotic
therapy showed potential activity of amphotericin B,
voriconazole and posaconazole and no activity of itra-
conazole and the echinocandins which is similar to a
previous study [18]. The relevance of these in vitro
data is not clear because a correlation between MICs/
MECs and clinical outcome has not been documented
for fusariosis [2]. The MIC of voriconazole of 2 mg/L
is below the mode of 4 mg/L as described for F.
fujikuroi [19] and a retrospective analysis of 73 pa-
tients with invasive fusariosis showed a 47 % success
rate [20]. Indeed recently published guidelines recom-
mend voriconazole (AII) or amphotericin B (BII) as
treatment option for invasive fusariosis [21].
Conclusion
In summary, this report demonstrated that an opportunistic
invasive fungal infection may indicate an underlying cellular
immune impairment of the host. The unexpected invasive
infection with F. ramigenum in this case unmasked com-
plex combined humoral and cellular immunological
deficiencies. Moreover, this paper provides evidence
indicating F. ramigenum as a potential human oppor-
tunist especially in immunocompromised patients.
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CT-scan: Computed tomography; CRP: C-reactive protein; ESR: Erythrocyte
sedimentation rate; BAL: Broncho-alveolar lavage; SGA: Sabouraud’s glucose
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susceptibility; MIC: Minimum inhibitory concentration; IFN γ: Gamma-
interferon; CARD9: Caspase recruitment domain-containing protein 9.
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